- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Branded ACS Therapies to Grab Market Share from Generics, Says Report
September 2, 2015.
While generic acute coronary syndrome (ACS) drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60 percent of the total market between 2015 and 2019, according to a report by Frost & Sullivan.
A Competitive Analysis of the Global Acute Coronary Syndrome Therapeutics Market finds that the market earned revenues of $13.95 billion in 2014 and estimates this to reach $33.54 billion in 2021 as a result of the development and launch of novel pipeline products.
The ACS therapeutics market consists of approximately 30 marketed branded drugs and hundreds of generics. The US marketis the largest in terms of revenues, driven primarily by incidence rates of ACS and the healthcare reimbursement system. The European market follows closely, with Germany, Italy and the UK offering the highest growth potential for both generic and branded dugs.
For more information visit http://corpcom.frost.com/forms/EU_PR_AZanchi_MB06-52_14Aug15.
